Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01691846 · ClinicalTrials.gov registry record · Phase 3
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT01691846 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 200 participants.
The verdict
NCT01691846, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
This multicenter, randomized, double-blind, placebo-controlled study will assess the efficacy, safety and tolerability of aleglitazar plus metformin combination therapy compared with placebo plus metformin in patients with type 2 diabetes mellitus who are inadequately controlled with metformin monotherapy. Patients will be randomized to receive oral doses of 150 mcg aleglitazar once daily or placebo. The anticipated time on study treatment is 26 weeks.
Interventions
- DRUG aleglitazar+metformin
- DRUG placebo+metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01691846
The ClinicalTrials.gov registry entry for NCT01691846 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which aleglitazar+metformin is the first listed.
NCT01691846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01691846 about?
NCT01691846 is a clinical study titled "A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone". This multicenter, randomized, double-blind, placebo-controlled study will assess the efficacy, safety and tolerability of aleglitazar plus metformin combination therapy compared with placebo plus metformin in patients with type 2 diabetes mellitus who are inadequately controlled with metformin monot...
What is the current status of trial NCT01691846?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2012-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01691846?
The interventions under investigation include: aleglitazar+metformin (DRUG), placebo+metformin (DRUG).
Who is sponsoring clinical trial NCT01691846?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.